Podcast: Optimizing CLL Care: Pharmacist-Led Strategies for Treatment Selection and Toxicity Management
Tracking # 20-1337984
What you'll learn
Upon completion of this activity, participants should be able to:
- Provide informed treatment recommendations as part of the care team to maximize efficacy and minimize intolerance of novel agents in CLL
- Develop evidence-based dose modification and supportive care strategies for managing novel CLL treatment–related toxicities
- Implement pharmacist-led patient education approaches to enhance treatment understanding and promote self-monitoring of adverse events
- Describe the unique role of pharmacists as part of the interprofessional team in enhancing patient care
Course overview
Chronic lymphocytic leukemia (CLL) is a hematologic malignancy characterized by an accumulation of abnormal immature or partially mature B lymphocytes in the blood and bone marrow (Wyatt et al, 2025). The introduction of targeted oral oncolytic therapies has shifted the treatment landscape for CLL, with oral agents now considered the standard first-line therapy. While these therapies provide an efficacious and convenient option for patients, they are associated with a range of toxicities that necessitate careful monitoring. Pharmacists play a crucial role in providing a comprehensive treatment approach to help navigate medication access, monitor safety and patient response, provide patient education, and optimize adherence (Wyatt et al, 2025; Upchurch & Muluneh, 2024). In this podcast, Kelsey Marciano, PharmD, BCOP, Clinical Pharmacy Specialist at UCHealth, will explore pharmacist-led strategies for treatment selection and toxicity management to optimize CLL care.
Subject areas
This course counts toward the state boards and subject areas below.
Florida Board of Pharmacy
Pharmacist
Registered Pharmacy Technician
Michigan Board of Pharmacy
Pharmacist
Pharmacist Special Volunteer
Pharmacy Technician
Pharmacy Technician Special Volunteer
New Hampshire Board of Pharmacy
Pharmacist
Disclosure statements
DISCLOSURE OF RELEVANT FINANCIAL INFORMATION WITH INELIGIBLE COMPANIES
i3 Health endorses the standards of the ACPE that require everyone in a position to control the content of a CPE activity to disclose all financial relationships with ineligible companies that are related to the content of the CPE activity. CPE activities must be balanced, independent of commercial bias, and promote improvements or quality in health care. All recommendations involving clinical medicine must be based on evidence accepted within the medical profession.
A conflict of interest is created when an individual has an opportunity to affect CPE content about products or services of an ineligible company with which he/she has a financial relationship, which therefore may bias their opinions and teaching. This may include receiving a salary, royalty, intellectual property rights, consulting fee, honoraria, stocks, or other financial benefits.
i3 Health will identify, review, and mitigate all relevant financial relationships that speakers, authors, or planners disclose prior to an educational activity being delivered to learners. Disclosure of a relationship is not intended to suggest or condone bias in any presentation but is made to provide participants with information that might be of potential importance to their evaluation of a presentation. i3 Health does not endorse any products or services.
Relevant financial relationships exist between the following individuals and ineligible companies:
The i3 Health planners, reviewers, and managers have nothing to disclose.
Kelsey Marciano, PharmD, BCOP, has no relevant financial relationships to disclose.
i3 Health has mitigated all relevant financial relationships.
Continuing Pharmacy Education
i3 Health has approved this knowledge-based activity for 0.75 ACPE CE hours. The Universal Activity Number for this activity is JA0008128-0000-25-035-H01-P. Pharmacy CE credits can be submitted to the NABP upon successful completion of the activity and the evaluation by providing your NABP ID and DOB, which must be submitted within 60 days of completion.
¿Take it Here
- This course reports to CE Broker immediately upon completion.
- Complete all courses at your own pace online.
- Quality and enjoyable courses.
- Modern experience, accessible from any device.
- All courses affordably priced.